140 related articles for article (PubMed ID: 2699627)
1. Ha-ras oncogene product in human oral squamous cell carcinoma.
Oku N; Shimada K; Itoh H
Kobe J Med Sci; 1989 Dec; 35(5-6):277-86. PubMed ID: 2699627
[TBL] [Abstract][Full Text] [Related]
2. Ha-ras oncogene product in human gastric carcinoma: correlation with invasiveness, metastasis or prognosis.
Tahara E; Yasui W; Taniyama K; Ochiai A; Yamamoto T; Nakajo S; Yamamoto M
Jpn J Cancer Res; 1986 Jun; 77(6):517-22. PubMed ID: 3089984
[TBL] [Abstract][Full Text] [Related]
3. RAS oncogene product expression in normal and malignant oral mucosa.
Freer E; Savage NW; Seymour GJ; Dunn TL; Lavin MF; Gardiner RA
Aust Dent J; 1990 Apr; 35(2):141-6. PubMed ID: 2189381
[TBL] [Abstract][Full Text] [Related]
4. Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Nictolis MD; Romanini C; Biagini G
Anticancer Res; 1998; 18(1B):609-13. PubMed ID: 9568185
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of oncogene product expression in human lung cancer].
Dosaka-Akita H; Harada M; Miyamoto H; Kawakami Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1441-7. PubMed ID: 1331597
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers--personal experience. Ha-ras P21 in neuroblastoma: a new marker associating to patient's prognosis].
Tanaka T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):143-50. PubMed ID: 1987897
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas.
Fillies T; Woltering M; Brandt B; Van Diest JP; Werkmeister R; Joos U; Buerger H
Oncol Rep; 2007 Feb; 17(2):355-9. PubMed ID: 17203174
[TBL] [Abstract][Full Text] [Related]
9. [Studies on ras P21 expression and mutation at 12th codon of C-Ha-ras oncogene in squamous cell carcinoma of the larynx].
Yang Q
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(4):209-12, 251. PubMed ID: 8167038
[TBL] [Abstract][Full Text] [Related]
10. [Oncoprotein p21-ras expression in epidermoid carcinoma of the laryngopharynx].
Baldo Sierra C; Núñez Batalla F; Domínguez O; Suárez Nieto C; Alvarez Alvarez I; Fresno Forcelledo M; López Larrea C
Acta Otorrinolaringol Esp; 1993; 44(3):165-8. PubMed ID: 8357627
[TBL] [Abstract][Full Text] [Related]
11. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
Agarwal R; Mohan RR; Ahmad N; Mukhtar H
Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
[TBL] [Abstract][Full Text] [Related]
12. [Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer].
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Ueno Y; Yamashita H; Nomura K; Ichiguchi O
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2271-5. PubMed ID: 1656890
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of ras p21 and c-myc p62 in colonic adenomas and carcinomas.
Agnantis NJ; Apostolikas N; Sficas C; Zolota V; Spandidos DA
Hepatogastroenterology; 1991 Jun; 38(3):239-42. PubMed ID: 1937363
[TBL] [Abstract][Full Text] [Related]
14. Valuation of exfoliative cytology as prediction factor in oral mucosa lesions.
Brunotto M; Zárate AM; Cismondi A; Fernández Mdel C; Noher de Halac RI
Med Oral Patol Oral Cir Bucal; 2005 Jul; 10 Suppl 2():E92-102. PubMed ID: 15995578
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors.
Miao TJ; Wang Z; Sang N
Eur Urol; 1991; 20(4):307-10. PubMed ID: 1814747
[TBL] [Abstract][Full Text] [Related]
16. Interaction between transforming growth factor-alpha and c-Ha-ras p21 in progression of human gastric carcinoma.
Yamamoto T; Hattori T; Tahara E
Pathol Res Pract; 1988 Nov; 183(6):663-9. PubMed ID: 3065747
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of p53 and bcl-2 oncoprotein expression in precancerous lesions of the oral cavity.
Sulkowska M; Famulski W; Chyczewski L; Sulkowski S
Neoplasma; 2001; 48(2):94-8. PubMed ID: 11478700
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa.
Visca P; Alò PL; Del Nonno F; Botti C; Trombetta G; Marandino F; Filippi S; Di Tondo U; Donnorso RP
Clin Cancer Res; 1999 Dec; 5(12):4111-8. PubMed ID: 10632348
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J
J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786
[TBL] [Abstract][Full Text] [Related]
20. Low levels of ras p21 oncogene expression correlates with clinical outcome in head and neck squamous cell carcinoma.
Field JK; Yiagnisis M; Spandidos DA; Gosney JR; Papadimitriou K; Vaughan ED; Stell PM
Eur J Surg Oncol; 1992 Apr; 18(2):168-76. PubMed ID: 1582509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
